Anti-PD-1-related pneumonitis during cancer immunotherapy

New England Journal of Medicine

Volumn 373, Issue 3, 2015, Pages 288-290

  Nishino, Mizuki ^a   Sholl, Lynette M ^a   Hodi, F Stephen ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; GLUCOCORTICOID; INFLIXIMAB; IPILIMUMAB; NIVOLUMAB; PROGRAMMED DEATH 1 RECEPTOR; MONOCLONAL ANTIBODY;

ADULT; ADULT RESPIRATORY DISTRESS SYNDROME; AGED; BRONCHIECTASIS; CANCER IMMUNOTHERAPY; CASE REPORT; DOSE RESPONSE; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; HUMAN; INTERSTITIAL PNEUMONIA; INTUBATION; LETTER; MALE; MELANOMA; MIDDLE AGED; MULTIPLE CYCLE TREATMENT; PNEUMONIA; PRIORITY JOURNAL; ADVERSE EFFECTS; ANTAGONISTS AND INHIBITORS; CHEMICALLY INDUCED; IMMUNOLOGY; IMMUNOTHERAPY; LUNG; NEOPLASMS; PATHOLOGY; RADIOGRAPHY;

ADULT; AGED; ANTIBODIES, MONOCLONAL; FEMALE; HUMANS; IMMUNOTHERAPY; LUNG; MALE; MIDDLE AGED; NEOPLASMS; PNEUMONIA; PROGRAMMED CELL DEATH 1 RECEPTOR;

EID: 84937053577     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMc1505197     Document Type: Letter

References (5)

1. Topalian SL, Hodi FS, Brahmer J.R., et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 2012; 366:2443-54.
2. Rizvi NA, Mazières J, Planchard D., et al. Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial. Lancet Oncol 2015; 16:257-65.
3. Topalian SL, Sznol M, McDermott D.F., et al. Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. J Clin Oncol 2014; 32:1020-30.
4. Robert C, Ribas A, Wolchok J.D., et al. Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumabrefractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial. Lancet 2014; 384:1109-17.
5. American Thoracic Society, European Respiratory Society. American Thoracic Society/European Respiratory Society International Multidisciplinary Consensus Classification of the Idiopathic Interstitial Pneumonias: this joint statement of the American Thoracic Society (ATS), and the European Respiratory Society (ERS) was adopted by the ATS board of directors, June 2001 and by the ERS Executive Committee, June 2001. Am J Respir Crit Care Med 2002; 165:277-304.